Cart
sales@molnova.com
Mast cell degranulating peptide (28-49)
CAS No. 65636-54-6
Mast cell degranulating peptide (28-49) ( )
Catalog No. M30267 CAS No. 65636-54-6
Mast cell degranulating peptide (28-49) is a bee venom depolarizer that can improve the cGMP content of cerebellum tablets in mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameMast cell degranulating peptide (28-49)
-
NoteResearch use only, not for human use.
-
Brief DescriptionMast cell degranulating peptide (28-49) is a bee venom depolarizer that can improve the cGMP content of cerebellum tablets in mice.
-
DescriptionMast cell degranulating peptide (28-49) is a bee venom depolarizer that can improve the cGMP content of cerebellum tablets in mice.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
RecptorIC50: cGMP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number65636-54-6
-
Formula Weight2591.3
-
Molecular FormulaC110H196N40O24S4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Ahnert G, et al. Investigations on the mechanism of cyclic guanosine monophosphate increase due to depolarizing agents as studied with sea anemone toxin II in mouse cerebellar slices. Naunyn Schmiedebergs Arch Pharmacol. 1979 Jun;307(2):159-66.
molnova catalog
related products
-
Disodium 5'-inosinat...
Inosine monophosphate or inosinic acid is the ribonucleotide of hypoxanthine and the first nucleotide formed during purine synthesis.
-
36-Dihydroxyflavone
36-Dihydroxyflavone?suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.
-
Mogroside III-A2
Mogroside III-A2 exhibits inhibitory effects with IC50 values of 346-400 mol ratio/32 pmol TPA. and shows weak inhibitory effects on activation of (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.
